LUPRON DEPOT® -3 Month 11.25 mg (leuprolide acetate for depot suspension) 3-MONTH FORMULATION
ثبت نشده
چکیده
Leuprolide acetate is a long-acting GnRH analog. A single injection of LUPRON DEPOT–3 Month 11.25 mg will result in an initial stimulation followed by a prolonged suppression of pituitary gonadotropins. Repeated dosing at quarterly (LUPRON DEPOT–3 Month 11.25 mg) intervals results in decreased secretion of gonadal steroids; consequently, tissues and functions that depend on gonadal steroids for their maintenance become quiescent. This effect is reversible on discontinuation of drug therapy.
منابع مشابه
A 6-month depot formulation of leuprorelin acetate proves successful in daily practice
The established agent leuprorelin acetate can be administered in combination with a novel biodegradable polymer matrix (Atrigel delivery system) to reduce testosterone levels in men with advanced hormone-dependent prostate cancer. Since 2007, this new formulation is available as a 6-month depot (Eligard 45 mg). The results of a recent non-interventional study, investigating the efficacy and saf...
متن کاملSix-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some patients with localized disease. Long-acting gonadotropin releasing hormone (GnRH) agonists have become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and convenience of use. One-month, 3-month, and 4-m...
متن کاملLeuprorelin acetate in prostate cancer: a European update.
This review provides an update on leuprorelin acetate, the world's most widely prescribed depot luteinising hormone-releasing hormone analogue. Leuprorelin acetate has been in clinical use in the palliative treatment of prostate cancer for more than 20 years, but advances continue to be made in terms of convenience and flexibility of administration, and in the incorporation of leuprorelin aceta...
متن کاملEfficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard®/Depo-Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study
INTRODUCTION The 1-, 3- and 6- month biodegradable polymer matrix depot formulations of leuprorelin acetate (Eligard(®)/Depo-Eligard(®), Astellas Pharma Inc/BV) were shown to reduce testosterone and prostate-specific antigen levels and to be well tolerated in patients with advanced prostate cancer in several clinical trials. This study aimed at evaluating the efficacy, safety and tolerability o...
متن کاملEfficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan
OBJECTIVE Leuprorelin acetate (TAP-144-SR) is commonly used worldwide in prostate cancer patients. This study was conducted to assess the non-inferiority of a 6-month depot formulation of TAP-144-SR (TAP-144-SR [6M]) 22.5 mg to a 3-month depot formulation of TAP-144-SR (TAP-144-SR [3M]) 11.25 mg in prostate cancer patients in Japan. METHODS This was a 48-week Phase III, open-label, parallel-g...
متن کامل